SF3B1 encodes a core component of the U2 snRNP spliceosome, the molecular machine that recognizes branch points in pre-messenger RNA and defines where introns are removed. Mutations in SF3B1 are among the most frequent genetic lesions in myelodysplastic syndromes, a group of clonal blood disorders in which the bone marrow produces immature cells that fail to mature properly, and they are particularly associated with ring sideroblasts and aberrant erythropoiesis. Patients with SF3B1-mutant disease suffer from anemia that often becomes transfusion-dependent, yet strategies to restore terminal erythroid maturation in this setting remain limited. Luspatercept, a fusion protein that traps TGF-beta family ligands, has offered partial benefit, but the search for accessible, mechanism-defining interventions continues.

To model the disease, the team used a zebrafish sf3b1 knockdown system. Zebrafish embryos are transparent, develop rapidly, and carry erythroid reporter lines that allow researchers to watch red blood cell formation in real time. In the morphants, erythroid reporter expression collapsed and hemoglobinization was severely impaired, recapitulating the ineffective erythropoiesis characteristic of SF3B1-linked disease. When the researchers treated these embryos with As2S2, erythroid reporter expression returned and hemoglobinization was reinstated. The rescue was partial but persistent at later developmental stages, indicating that the compound does not merely mask the defect but partially reinstates the maturation program that sf3b1 deficiency disrupts.

The mechanism emerged from integrated transcriptomic and proteomic analyses. As2S2 remodels metabolic and translational programs in the deficient embryos, reshaping the cellular economy of developing red blood cells. More notably, the compound attenuates TGF-beta pathway activity, and the single most prominent change is the induction of smad7. Smad7 is an inhibitory Smad, a negative feedback regulator that blocks receptor-mediated phosphorylation of the canonical Smad2 and Smad3 signaling cascade. By upregulating smad7, As2S2 effectively applies a brake to hyperactive TGF-beta signaling, a pathway whose excessive activity is known to suppress terminal erythroid maturation.

To validate that this Smad7-dependent mechanism is genuinely therapeutic rather than incidental, the researchers performed comparative analysis with pharmacologic TGF-beta inhibition. The two interventions share an overlapping therapeutic axis, converging on the same TGF-beta-modulating mechanism. This convergence validates the Smad7-dependent pathway and reveals that As2S2 acts as an in vivo chemical probe, a small molecule that counteracts sf3b1-dependent erythroid failure through a defined molecular route. The team also notes that As2S2 shares a convergent TGF-beta-modulating mechanism with luspatercept, the clinically approved erythroid maturation agent, suggesting that the compound and the biologic rescue erythropoiesis through a common regulatory node.

The study is notable for its experimental design. Zebrafish have become an increasingly important model for hematologic disorders because their erythroid development is highly conserved with that of humans and their optical transparency permits quantitative imaging of blood cell formation. By combining a genetic knockdown model with reporter lines, transcriptomics, proteomics, and pharmacologic comparison, the researchers built a multi-layered evidence chain that links a clinical compound to a specific molecular mediator. The integrated omics approach revealed that As2S2 does not simply correct splicing, the primary defect caused by sf3b1 loss, but instead bypasses it by modulating downstream signaling, a strategy that may prove more tractable than attempting to restore spliceosome function directly.

Smad7 has long been recognized as a rheostat of TGF-beta biology, but its role in erythroid maturation has been underappreciated. The new findings highlight Smad7 as a candidate for therapeutic modulation in SF3B1-associated ineffective erythropoiesis. If Smad7 upregulation can be achieved safely in patients, whether through As2S2 or through other means, it may offer a way to counteract the TGF-beta-driven suppression of red cell maturation that contributes to anemia in myelodysplastic syndromes. The convergence with luspatercept suggests that Smad7 sits within the same regulatory circuit that biologic agents already exploit clinically.

Arsenic disulfide is distinct from arsenic trioxide, the form of arsenic that has already earned regulatory approval for acute promyelocytic leukemia. As2S2 is a mineral compound with a long history in traditional Chinese medicine and has been investigated in hematologic malignancies, but its application to spliceosome-mutant anemia represents a new therapeutic direction. The zebrafish model provides an efficient platform for testing such compounds in vivo, and the partial persistence of rescue at later developmental stages suggests that the effect is not merely transient. Further work will be needed to determine whether As2S2 can achieve similar erythroid maturation rescue in mammalian models and ultimately in patients with SF3B1-mutant myelodysplastic syndromes.

The findings carry broader implications for how researchers approach spliceosome-driven disease. Rather than attempting to repair the mutated spliceosome itself, an enormously difficult task given that SF3B1 is a core component of a large molecular machine, the As2S2 strategy identifies a downstream signaling pathway that can be modulated pharmacologically. This bypass approach may be applicable to other spliceosome-mutant disorders, and the identification of Smad7 as a mediator opens a concrete molecular target. The study also underscores the value of zebrafish as a discovery platform, allowing rapid in vivo screening of compounds that would be difficult to evaluate in cell culture alone.

Published as an open-access research article in Annals of Hematology, the study was supported by the National Natural Science Foundation of China, the Zhejiang Provincial Natural Science Foundation, and multiple Shanghai municipal programs. The authors declare no competing interests. As research continues into the molecular mechanisms of ineffective erythropoiesis, the convergence of an ancient mineral compound, a modern genetic model, and a defined signaling mediator offers a compelling example of how traditional pharmacology and contemporary molecular biology can illuminate each other. Whether As2S2 will translate into clinical benefit for patients with SF3B1-mutant myelodysplastic syndromes remains to be determined, but the identification of Smad7 as a pharmacologically tractable mediator provides a clear path forward.

Subject of Research: As2S2 restores erythroid maturation in sf3b1-deficient zebrafish by upregulating smad7

Article Title: As2S2 restores erythroid maturation in sf3b1-deficient zebrafish by upregulating smad7

Article References: Wu, F., Cai, S., Luo, Q., Li, H., Tao, Y., Li, J., Chen, Y., Wang, Y., Xu, H., Hu, K., Ding, N., Ni, R., Jin, R., Liu, M., Shi, Y., Yu, L., & Lu, J. (2026). As2S2 restores erythroid maturation in sf3b1-deficient zebrafish by upregulating smad7. Annals of Hematology. https://doi.org/10.1007/s00277-026-07324-2

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07324-2

Keywords: As2S2, restores, erythroid, maturation, sf3b1-deficient, zebrafish, upregulating, smad7, scientific research